Skip to main
SOPH
SOPH logo

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics SA has demonstrated a solid trajectory of financial improvement, highlighted by an increase in gross margins from 68% to 72% in FY'23, driven by reduced computing and storage costs as well as a decrease in headcount. The company achieved over 40% growth in critical regions and expanded its core customer base to 450, with an anticipated 30%+ revenue growth in the near term as demand for sequencing continues to rise. Management expects to reach profitability within two years, bolstered by effective cost controls and a strategic shift towards higher-margin software offerings, indicating a robust outlook for financial performance beyond 2024.

Bears say

Sophia Genetics SA is facing a challenging environment within the Life Science Tools and Diagnostics sector, characterized by inventory destocking, a slower recovery in China, and cautious spending from the biopharma and biotech industries. Despite the company’s operational advantages as a SaaS provider and minimal exposure to those particular headwinds, the potential for longer-than-expected inventory destocking at customer levels poses a risk to future guidance and financial estimates. Additionally, macroeconomic factors, including inflation, currency fluctuations, and changes in regulatory conditions, may adversely impact the company’s performance going forward.

SOPH has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Buy based on their latest research and market trends.

According to 7 analysts, SOPH has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.